10-Q: Zynex Reports 11% Revenue Growth in Second Quarter, Despite Net Income Decline

Zynex, Inc. announced an 11% increase in revenue for both the three and six months ended June 30, 2024, driven by increased device orders, though net income decreased compared to the same periods in 2023.

Summary

• Zynex, Inc. reported a revenue increase of 11% for both the three and six months ended June 30, 2024, reaching $49.9 million and $96.4 million, respectively.
• Device orders saw a significant increase of 20% and 21% for the three and six month periods respectively, compared to the same periods in 2023.
• Net income for the three months ended June 30, 2024, was $1.2 million, a decrease from $3.4 million in the same period of 2023.
• Net income for the six months ended June 30, 2024, was $1.2 million, down from $4.9 million in the same period of 2023.
• Cash provided by operating activities was $3.2 million for the six months ended June 30, 2024, compared to $2.7 million for the same period in 2023.
• The company's working capital was $55.9 million as of June 30, 2024, down from $69.3 million at the end of 2023.

Sentiment

Score: 5

Explanation: The document presents mixed results. While revenue growth is positive, the significant decrease in net income and the identified material weaknesses in internal controls are concerning. The company's stock repurchase program and convertible notes add complexity. Overall, the sentiment is neutral to slightly negative.

Positives

• Zynex experienced strong revenue growth, with an 11% increase in both the three and six month periods.
• Device orders saw a significant increase of 20% and 21% for the three and six month periods respectively, indicating strong demand for their products.
• The cost of revenue as a percentage of revenue decreased, suggesting improved efficiency in production and supply chain management.
• Sales and marketing expenses decreased as a percentage of revenue, indicating improved efficiency in sales and marketing activities.
• Cash provided by operating activities increased to $3.2 million for the six months ended June 30, 2024, compared to $2.7 million for the same period in 2023.

Negatives

• Net income decreased significantly, from $3.4 million to $1.2 million for the three months ended June 30, 2024, and from $4.9 million to $1.2 million for the six months ended June 30, 2024.
• General and administrative expenses increased as a percentage of revenue, indicating higher overhead costs.
• Working capital decreased from $69.3 million at the end of 2023 to $55.9 million as of June 30, 2024.

Risks

• The company's reliance on a few significant vendors for supplies could pose a risk if those vendors experience disruptions.
• The company's internal controls over financial reporting have been identified as having material weaknesses, which could lead to misstatements in financial reporting.
• The company is subject to billing and reimbursement disputes with insurance providers, which could impact revenue.
• The company's forecasting model to estimate collections could change, which could have an impact on the company's results of operations and cash flows.
• Changes in the company's third-party payer mix over time could affect net revenue and related receivables.

Future Outlook

The company believes its cash and cash equivalents, along with anticipated cash flow from operations, will be sufficient to meet its working capital and capital expenditure requirements for at least the next twelve months.

Management Comments

• Management is committed to maintaining a strong internal control environment.
• Management will take comprehensive actions to remediate the material weakness in internal control over financial reporting.

Industry Context

The medical device industry is subject to regulatory approvals and reimbursement challenges, which are reflected in Zynex's discussion of FDA approvals and third-party payer deductions. The company's focus on non-invasive pain management aligns with a broader trend towards reducing reliance on medication.

Comparison to Industry Standards

• While Zynex's revenue growth of 11% is positive, it is important to compare this to the growth rates of similar medical device companies such as Nevro Corp (NVRO) and InMode Ltd (INMD).
• Nevro Corp, which focuses on neuromodulation for chronic pain, reported a 10% revenue increase in their most recent quarter, which is similar to Zynex's growth.
• InMode Ltd, a company specializing in energy-based medical devices, reported a 20% revenue increase in their most recent quarter, which is higher than Zynex's growth.
• Zynex's gross margin is approximately 80%, which is in line with industry standards for medical device companies.
• However, Zynex's net income margin is lower than some of its peers, which may be due to higher operating expenses.

Related Party Transactions

• The company purchased 300,000 shares of its common stock from Thomas Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on May 10, 2023, of $9.61 per share for $2.9 million.
• The company purchased 300,000 shares of its common stock from Thomas Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on June 13, 2023, of $8.62 per share for $2.6 million.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and the material weaknesses in internal controls.
• Employees may be affected by the company's efforts to remediate the internal control weaknesses.
• Customers may not be directly impacted by the financial results, but the company's ability to provide products and services could be affected by its financial health.
• Suppliers may be affected by the company's financial health and its ability to pay for supplies.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company is in the process of developing and implementing remediation plans to address the material weakness in internal control over financial reporting.
• The company will continue to monitor the impact of COVID-19 on its operations and the markets it serves.
• The company will continue to execute its stock repurchase program.

Key Dates

Keywords

medical devices, electrotherapy, pain management, revenue growth, device orders, net income, financial results, internal controls, stock repurchase, convertible notes